Head-to-head Phase 3 clinically confirmed that the treatment of moderate to severe psoriasis with anti-IL-17 monoantigen Bimekizumab was better than TNF monoantigen

At the European Conference on Dermatology and Sexually Ills, biopharmaceutical company UMB announced the detailed results of the Head-to-Head Phase 3 BE SURE study, which showed that adult patients treated with IL-17A and IL-17F monoantigen bimekizumab had a higher rate of moderate to severe plaque psoriasis in adult patients than those who were resistant to TNF-α monoantigen adamu monoantigen (Humira, Sumerian).
Bimekizumab simultaneously targets both IL-17A and IL-17F (Photo Source: BE SURE study reaches all major and secondary endpoints.
results showed that at the 16th week of treatment, 86.2% of patients treated with bimekizumab had almost skin loss (PASI 90), while 47.2% of patients treated with Adamo monoantigen (p .lt;0.001).
addition, at the 16th week, 85.3 per cent of patients treated with bimekizumab reached IGA 0/1, while 57.2 per cent of patients treated with Adamo monoantigen (p .lt;0.001).
Patients treated with bimekizumab had a higher rate of complete skin loss (PASI 100) than those treated with adamo monotherapy: 60.8% and 23.9% at 16 weeks and 66.8% and 29.6% at 24 weeks, respectively (p -lt;0.001 per comparison).
in two bimekizumab study groups, patients treated with bimekizumab had a response rate of PASI 90, PASI 100 and IGA 0/1 up to week 56.